Novartis AG has experienced a mixed bag of reviews, with analysts presenting an average rating of 'Reduce', while the company's strong performance in FY24 results in valuable shares. The stock has risen 5% since Q4 earnings, and earnings consensus have been beat due to a surge in drug sales. Several investment companies, such as Alliance Wealth Advisors LLC, Baldwin Wealth Partners LLC, Stock Yards Bank & Trust Co. and others, have made significant transactions involving Novartis. The pharmaceutical giant's performance is reportedly even stronger than its earnings suggest. Despite a downgrade by StockNews.com, Novartis continues to hold strong value. Recent Q4 earnings, despite beating estimates, resulted in a dip in the stock price. Dividends are expected to increase to $3.50, indicating a positive outlook. However, the market is casting a skeptical eye on the disappointing performance of Novartis' Pluvicto.
Novartis saw a stock dive due to an $800 million write-down, but is still considered a worthy investment by many. There is a focus on the company’s strong 2024 financial performance and innovative milestones, such as in-licensing PTCT's
Huntington's Disease Drug for $2.9 billion. Yet, the stock was downgraded by HSBC due to the conservative approach to capital arrangements.
Novartis Stocks News Analytics from Tue, 09 Jul 2024 07:00:00 GMT to Sat, 08 Feb 2025 22:01:01 GMT -
Rating 3
- Innovation 6
- Information 7
- Rumor 1
